Adrienne Graves, PhD

Dr. Adrienne Graves is a visual scientist by training and a global industry leader in ophthalmology. As the former CEO of Santen Inc., the US subsidiary of Santen Ltd., she successfully established a strong global presence, brought multiple ophthalmic products through development to approval and commercialization, and led global teams through successful acquisitions and partnerships. At Santen, Dr. Graves served as Sr. VP of Worldwide Clinical Development (US, Europe, and Japan) for 7 years and CEO for 8 years. Prior to Santen, she spent 9 years at Alcon, joining as Sr. Scientist and progressing through roles of increasing responsibility, including Director of Clinical Development and Director of International Ophthalmology. Dr. Graves currently serves as an Independent Director on the boards of Iveric, Akorn, Nicox, Surface Pharmaceuticals, Oxurion, and Greenbrook TMS Healthcare. She previously held board positions at Encore Vision (2011 – 2017; acquired by Novartis), Envisia (2014 – 2017; assets acquired by Aerie Pharmaceuticals), TearLab (2005 – 2018), and Aerpio (2012 – 2017). Dr. Graves also serves on the following Foundation Boards: American Society of Cataract and Refractive Surgery (ASCRS), Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, and the Foundation Fighting Blindness Retinal Degeneration Fund. She co-founded OWL and Glaucoma 360. Dr. Graves received an AB with Honors in Psychology from Brown University, a Ph.D. in Psychobiology from the University of Michigan, and she completed a Postdoctoral Fellowship in Visual Neuroscience at the University of Paris.